Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AxoGen ( (AXGN) ) just unveiled an announcement.
On June 18, 2025, AxoGen, Inc. held its annual meeting of shareholders where five proposals were voted on, including the election of eight directors, ratification of Deloitte & Touche LLP as auditors, approval of executive compensation, amendment of the long-term incentive plan, and the frequency of future votes on executive compensation. The outcomes of these votes are expected to influence the company’s governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AXGN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.
Spark’s Take on AXGN Stock
According to Spark, TipRanks’ AI Analyst, AXGN is a Neutral.
AxoGen’s overall score reflects a company in transition, with strong revenue growth and strategic plans offset by technical weakness and poor valuation. The earnings call provided positive guidance, but ongoing profitability challenges weigh heavily.
To see Spark’s full report on AXGN stock, click here.
More about AxoGen
AxoGen, Inc. operates in the medical industry, focusing on developing and commercializing innovative surgical solutions for peripheral nerve injuries. The company is known for its regenerative medicine products that support nerve repair and regeneration, catering primarily to healthcare providers and patients requiring nerve repair surgeries.
Average Trading Volume: 593,826
Technical Sentiment Signal: Sell
Current Market Cap: $423.1M
Learn more about AXGN stock on TipRanks’ Stock Analysis page.